Electra Therapeutics, Inc.: Cormorant Asset Management, LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Cormorant Asset Management disclosed a stake exceeding 5% in Electra Therapeutics under a Schedule 13G filing with the SEC (accession 0001172661-26-005295). The 13G designation indicates a passive position rather than an activist one, though the filing as summarized did not specify the exact share count or percentage held. Crossing the 5% threshold makes Cormorant a significant holder and triggers ongoing disclosure obligations, including amendments if its position shifts materially. Investors will watch for further filings that detail the precise size of the stake and any changes in subsequent periods.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Electra Therapeutics, Inc., Cormorant Asset Management, LP